CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor NK Cell Based Therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor NK Cell Based Therapy, covering 2019-05-07 to 2019-05-07. Get the full timeline:
Most recent: Clinical Trial Update: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR [NA]